SIGNS that the biotechnology industry is not growing as fast in the mid 1990s as it did in the 1980s have the industry's members, academic leaders, and investors worried. They have joined in an effort to halt any further erosion and to shape a national agenda to ensure United States preeminence in biotechnology. If the meeting they held in Washington, DC, described as the National Biotechnology Summit, did not exactly allay the industry's fears for the future, it did examine some of the problems the industry faces.
Speaker after speaker pointed with alarm to cuts in federal funding for medical research, delays in drug approval, and doubts about the way new drug price controls, likely to be incorporated into health system reform legislation, may work.
More than one speaker called up the specter of an administration that they say views new medical technologies as expensive toys to be